Related News
Home 禄 Business 禄 Manufacturing
GSK seeks 16% stake in Aspen to grow market
By Tiisetso Motsoeneng |
May 13, 2009, Wednesday
|
Print Edition
Print Edition
GLAXOSMITHKLINE will take a 16-percent stake in Africa's biggest generic drug maker, Aspen Pharmacare, to expand its emerging market footprint in a deal worth 3.47 billion rand (US$418 million).
The deal, based on a transfer of assets rather than cash, cements an existing relationship between the companies and underlines Glaxo's commitment to growing in emerging markets as part of a strategy to diversify its business.
The companies said yesterday Aspen would issue 68.5 million new shares to Glaxo in exchange for Glaxo's manufacturing plant in Bad Oldesloe, Germany, and eight specialist medicines.
Aspen will also distribute Glaxo products in South Africa - which generated sales of about 45 million pounds (US$68.3 million) last year - and the companies will team up to market and sell prescription drugs in the rest of Africa, where revenue totaled about 65 million pounds in 2008. The world's second-largest seller of prescription drugs will get a seat on Aspen's board.
"Extending our strategic relationship with Aspen supports GSK's strategy to accelerate sales growth in emerging markets," Abbas Hussain, Glaxo's head of emerging markets, said in a statement.
Based on Aspen's closing share price on Monday, the deal is worth 3.47 billion rand.
"Strategically it looks very good for Aspen," said Andrew Joannou, a portfolio manager at Cape Town-based Afena Capital.
The deal, based on a transfer of assets rather than cash, cements an existing relationship between the companies and underlines Glaxo's commitment to growing in emerging markets as part of a strategy to diversify its business.
The companies said yesterday Aspen would issue 68.5 million new shares to Glaxo in exchange for Glaxo's manufacturing plant in Bad Oldesloe, Germany, and eight specialist medicines.
Aspen will also distribute Glaxo products in South Africa - which generated sales of about 45 million pounds (US$68.3 million) last year - and the companies will team up to market and sell prescription drugs in the rest of Africa, where revenue totaled about 65 million pounds in 2008. The world's second-largest seller of prescription drugs will get a seat on Aspen's board.
"Extending our strategic relationship with Aspen supports GSK's strategy to accelerate sales growth in emerging markets," Abbas Hussain, Glaxo's head of emerging markets, said in a statement.
Based on Aspen's closing share price on Monday, the deal is worth 3.47 billion rand.
"Strategically it looks very good for Aspen," said Andrew Joannou, a portfolio manager at Cape Town-based Afena Capital.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
